Register
Login:
Share:
Email Facebook Twitter

Leading commentator Josh Mahony from IG - are we seeing a US$ revaluation? Watch here

Leading commentator Josh Mahony from IG - are we seeing a US$ revaluation?


Member Info for inanaco


Premium Member

Send a private message to inanaco

Member Since: Wed, 19th Oct 2011

Number of Share Chat Posts (all time): 24,788
Number of Share Chat Posts (last 30 days): 124

Last Posted: Today 15:27


Post Distribution over the last 30 days




Today 15:27

appreciate that Rats, i was just picking up on the science linking.... like i said, any other connections at this stage are speculative and "IMHO" posting is acceptable, as an opinion.

but the science is factual .... and requires a post that is as factual as we can get it ... having two parties that agree is better than one, ie Boom and nana
Today 15:12

I really have to be careful, as you well know, a discussion on here even without any personal attacks from my side could be classed as a suspension offence.
Today 15:02

sorry should have added """ rats post"""
Today 15:02

clearly you are not reading what was written ........ which is why we have so many discussions, however i do not want any drawn out posts, as Admin will see this as distruptive.

""" Look at the survival figures on afatinib from 2013 for example - https://www.lungcancerfoundation.org/2013/01/boehringer-ingelheims-lung-cancer-compound-granted-fda-priority-review/
Could SCIB2 give this one a boost? A lot to talk about, but I believe there may be even more going on behind the scenes than I thought.
Today 14:55

not getting into any drawn out conclusions, only replied to Rats post ...... that indicated a tie up with Afatinib which as i have explained IMHO has no synergy with immunobody.

Regarding other PD1 products anything is possible, as it has synergy, however at present that is not possible to buy over the counter, like keytruda, so any use would require a "deal"
Today 14:32

is not just to delay but to destroy the cancer .... or turn it into a stable condition that does not progress (in balance with the immune system) so far those results have been seen in our trials. With 8 patients past the 5 year gold standard.

Afatinib has demonstrated a significant delay in tumour growth versus the best-in-class chemotherapy, which resulted in 11.1 months progression free survival (PFS) vs. 6.9 months in the comparator arm.
Today 14:18

synergy with this type of treatment, and IMHO i cannot see how it would interact

Boehringer Ingelheim

Afatinib is a type of cancer growth blocker called a protein tyrosine kinase inhibitor (TKI). Tyrosine kinases are proteins that stimulate cells to grow. Afatinib blocks tyrosine kinases and also blocks epidermal growth factor receptor proteins in cancer cells. So afatinib is also called an EGFR-TK inhibitor.
Wed 11:32

Will Work .........

Improving Response Rates with OncoSec’s ImmunoPulse® IL-12
Data from the JCI Insights study shows that only 5.6% of patients with low peCTL responded to anti-PD-1 alone. In combination with anti-CTLA-4, the response rate improved to 35%. “At OncoSec, we believe that our lead product candidate, ImmunoPulse® IL-12, may improve this response rate even further, said OncoSec President and CEO, Punit Dhillon.

In preliminary studies, OncoSec has shown that ImmunoPulse® IL-12, in combination with anti- PD-1, can yield objective responses in patients with low frequencies of peCTL. Interim data from a phase II study, led by UCSF Principal Investigator Dr. Alain Algazi, showed a 48% best overall response rate from the combination of ImmunoPulse® IL-12 with pembrolizumab in the low peCTL population.

“We believe this combination melanoma trial is the first clinical trial to use this T cell biomarker to evaluate the clinical response of patients with low frequency of peCTL. To date, 48% of the patients evaluable in the interim data of our study showed partial or complete response to the combination", continued Mr. Dhillon. “These results continue to provide evidence that ImmunoPulse® IL-12, in combination with anti-PD-1 therapies, can improve response rates in advanced melanoma. We believe that these new results reinforce the relevance of the clinical data we presented in this difficult-to-target population, namely those unlikely to respond to anti-PD-1 monotherapy. The data from this study also further validates the approach we have taken in our upcoming PISCES trial; to treat patients that fail to respond to anti-PD-1 therapy alone.”


Sign up for Live Prices
Top Recommended
Hot Chat Topics
Top recommended posters in the last 30 days
Brombarb5,147
Wassatt2,829
Wisecrow2,197
DegsyAlmomd2,124
kenny1001,653
Troajan1,573
Lakshmi8881,449
ArielArrow1,236





Member Login

Forgotten your password?
Email:

Password:


Don't have an account? Click here to Register Free!




Datafeed and UK data supplied by NBTrader and Digital Look. While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.